Glial fibrillary acidic protein (GFAP)

Glial fibrillary acidic protein (GFAP) is an astrocyte structural protein. GFAP has been authorized as one of the biomarkers for mild traumatic brain injury (mTBI) and its level shows a correlation with the clinical severity after the injury.

already today!
Read more and
order below!

GFAP is a member of the type III intermediate filament that provides support and strength to cells and sustains the cell shape. In 2018, GFAP, together with Ubiquitin C-terminal hydrolase-L1 (UCH-L1), received approval as a biomarker for concussion in adults by the U.S. Food and Drug Administration (FDA). This represented a great milestone in the blood biomarker development for neurological disorders. Furthermore, it can be detected in serum already within the first few hours after a head injury.

HyTest offers several well-characterized monoclonal antibodies that are specific to GFAP and which may be used for the quantification of GFAP in serum, plasma, or CSF.

Learn more:
Cat# 4G25:Glial Fibrillary Acidic Protein, Antibody 

Do you need samples?

We are happy to make you an offer